All Stories

  1. Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts

    Article • Science Translational Medicine, December 2025, American Association for the Advancement of Science

    Khandan Keyomarsi

  2. Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer

    Article • npj Breast Cancer, January 2025, Springer Science + Business Media

    Khandan Keyomarsi

  3. Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer

    Article • Cancer Research, August 2024, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  4. STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response

    Article • Leukemia, March 2024, Springer Science + Business Media

    Khandan Keyomarsi

  5. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

    Article • Cancers, January 2024, MDPI AG

    Khandan Keyomarsi

  6. Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance

    Article • Nature Communications, January 2024, Springer Science + Business Media

    Khandan Keyomarsi

  7. Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis

    Article • Molecular Cancer Therapeutics, October 2023, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  8. Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All

    Article • Cancer Research, October 2023, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  9. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers

    Article • Cancer Research, June 2023, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  10. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

    Article • Clinical Cancer Research, June 2023, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  11. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer

    Article • JAMA Oncology, June 2023, American Medical Association (AMA)

    Khandan Keyomarsi

  12. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

    Article • Journal of Clinical Oncology, March 2023, American Society of Clinical Oncology (ASCO)

    Khandan Keyomarsi

  13. Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time

    Article • Cancer Research, January 2023, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  14. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer

    Article • Oncogene, November 2022, Springer Science + Business Media

    Khandan Keyomarsi

  15. CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2

    Article • Cancer Research, June 2022, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  16. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

    Article • Expert Opinion on Investigational Drugs, May 2022, Taylor & Francis

    Khandan Keyomarsi

  17. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study

    Article • International Journal of Cancer, March 2022, Wiley

    Khandan Keyomarsi

  18. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers

    Article • Oncogenesis, May 2021, Springer Science + Business Media

    Khandan Keyomarsi

  19. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration

    Article • Cancers, April 2021, MDPI AG

    Khandan Keyomarsi

  20. Regulation of the Cell Cycle by Kinases and Cyclins

    Article • August 2020, Taylor & Francis

    Khandan Keyomarsi

  21. Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers

    Article • American Society of Clinical Oncology Educational Book, May 2020, American Society of Clinical Oncology (ASCO)

    Khandan Keyomarsi

  22. Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age

    Article • Cancers, March 2020, MDPI AG

    Khandan Keyomarsi

  23. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer

    Article • British Journal of Cancer, January 2020, Springer Science + Business Media

    Khandan Keyomarsi

  24. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer

    Article • Annals of Surgery, August 2019, Wolters Kluwer Health

    Khandan Keyomarsi

  25. Arthur B. Pardee: In Memoriam (1921–2019)

    Article • Cancer Research, May 2019, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  26. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer

    Article • Clinical Cancer Research, March 2019, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  27. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies

    Article • Cancer Research, September 2018, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  28. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition

    Article • Clinical Cancer Research, September 2018, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  29. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy

    Article • Expert Opinion on Investigational Drugs, August 2018, Taylor & Francis

    Khandan Keyomarsi

  30. Leveraging MYC as a therapeutic treatment option for TNBC

    Article • Oncoscience, June 2018, Impact Journals, LLC

    Khandan Keyomarsi

  31. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes

    Article • BMC Genomics, February 2018, Springer Science + Business Media

    Khandan Keyomarsi

  32. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis

    Article • Genome Research, December 2017, Cold Spring Harbor Laboratory Press

    Khandan Keyomarsi

  33. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions

    Article • Targeted Oncology, December 2017, Springer Science + Business Media

    Khandan Keyomarsi

  34. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer

    Article • Cancer Research, November 2017, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  35. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer

    Article • Clinical Cancer Research, September 2017, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  36. Abstract 2060: Characterizing acquired resistance to palbociclib in breast cancer

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  37. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers

    Article • Nature Communications, June 2017, Springer Science + Business Media

    Khandan Keyomarsi

  38. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest

    Article • Molecular Cancer Therapeutics, June 2017, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  39. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer

    Article • Oncotarget, January 2017, Impact Journals, LLC

    Khandan Keyomarsi

  40. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation

    Article • Journal of Cancer, January 2017, Ivyspring International Publisher

    Khandan Keyomarsi

  41. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

    Article • Clinical Cancer Research, November 2016, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  42. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers

    Article • Molecular Cancer Research, September 2016, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  43. Cytoplasmic Cyclin E and Phospho–Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer

    Article • American Journal Of Pathology, July 2016, Elsevier

    Khandan Keyomarsi

  44. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion

    Article • Cell Cycle, May 2016, Taylor & Francis

    Khandan Keyomarsi

  45. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells

    Article • Cancer Research, February 2016, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  46. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness

    Article • Nature Communications, February 2016, Springer Science + Business Media

    Khandan Keyomarsi

  47. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer

    Article • Molecular Cancer Therapeutics, January 2016, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  48. Targeting the Cell Cycle in Breast Cancer

    Article • Breast Diseases A Year Book Quarterly, January 2016, Elsevier

    Khandan Keyomarsi

  49. PKCiota promotes ovarian tumor progression through deregulation of cyclin E

    Article • Oncogene, August 2015, Springer Science + Business Media

    Khandan Keyomarsi

  50. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

    Article • June 2015, Springer Science + Business Media

    Khandan Keyomarsi

  51. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

    Article • Investigational New Drugs, May 2015, Springer Science + Business Media

    Khandan Keyomarsi

  52. Staurosporine

    Article • January 2015, Springer Science + Business Media

    Khandan Keyomarsi

  53. Staurosporine

    Article • January 2015, Springer Science + Business Media

    Khandan Keyomarsi

  54. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

    Article • December 2014, Springer Science + Business Media

    Khandan Keyomarsi

  55. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

    Article • Cancer, October 2014, Wiley

    Khandan Keyomarsi

  56. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase

    Article • Oncogene, September 2014, Springer Science + Business Media

    Khandan Keyomarsi

  57. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells

    Article • Cell Cycle, August 2014, Taylor & Francis

    Khandan Keyomarsi

  58. 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

    Article • Nature Communications, March 2014, Springer Science + Business Media

    Khandan Keyomarsi

  59. Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells

    Article • Cancer Research, August 2013, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  60. Staurosporine is chemoprotective by inducing G 1 arrest in a Chk1- and pRb-dependent manner

    Article • Carcinogenesis, May 2013, Oxford University Press (OUP)

    Khandan Keyomarsi

  61. EVI1 splice variants modulate functional responses in ovarian cancer cells

    Article • Molecular Oncology, March 2013, Wiley

    Khandan Keyomarsi

  62. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer

    Article • January 2013, Springer Science + Business Media

    Khandan Keyomarsi

  63. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer

    Article • Cell Cycle, April 2012, Taylor & Francis

    Khandan Keyomarsi

  64. LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients

    Article • PLoS Genetics, March 2012, PLOS

    Khandan Keyomarsi

  65. P5-03-03: Identification of New Substrates for Breast Tumor Specific Low-Molecular-Weight Cyclin E Cyclin-Dependent-Kinase 2.

    Article • December 2011, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  66. Targeting low molecular weight cyclin E (LMW-E) in breast cancer

    Article • Breast Cancer Research and Treatment, June 2011, Springer Science + Business Media

    Khandan Keyomarsi

  67. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells

    Article • Cancer Gene Therapy, May 2011, Springer Science + Business Media

    Khandan Keyomarsi

  68. Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E

    Article • Cancer Research, March 2011, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  69. Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles

    Article • Journal of Carcinogenesis, January 2011, Medknow

    Khandan Keyomarsi

  70. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

    Article • Breast Diseases A Year Book Quarterly, January 2011, Elsevier

    Khandan Keyomarsi

  71. Staurosporine

    Article • January 2011, Springer Science + Business Media

    Khandan Keyomarsi

  72. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells

    Article • Cell Biology and Toxicology, September 2010, Springer Science + Business Media

    Khandan Keyomarsi

  73. The Neutrophil Elastase Inhibitor Elafin Triggers Rb-Mediated Growth Arrest and Caspase-Dependent Apoptosis in Breast Cancer

    Article • Cancer Research, September 2010, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  74. Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25C

    Article • Cancer Research, June 2010, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  75. Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification

    Article • Cancer Research, June 2010, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  76. A novel interaction between HER2/neu and cyclin E in breast cancer

    Article • Oncogene, May 2010, Springer Science + Business Media

    Khandan Keyomarsi

  77. Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors

    Article • Clinical Cancer Research, February 2010, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  78. Post-translational modification and stability of low molecular weight cyclin E

    Article • Oncogene, June 2009, Springer Science + Business Media

    Khandan Keyomarsi

  79. Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer

    Article • Clinical Cancer Research, May 2009, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  80. DEAR1 Is a Dominant Regulator of Acinar Morphogenesis and an Independent Predictor of Local Recurrence-Free Survival in Early-Onset Breast Cancer

    Article • PLoS Medicine, May 2009, PLOS

    Dr Stephen M Hewitt, Khandan Keyomarsi

  81. Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation

    Article • Cancer Research, March 2009, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  82. Overexpression of LMW cyclin E results in faster M phase progression via Cdc25C interaction leading to chromosome missegragation in breast cancer cells.

    Article • January 2009, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  83. CDK2 is required for LMW-cyclin E mediated murine mammary tumorigenesis.

    Article • January 2009, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  84. Cyclin E deregulation is an early event in the development of breast cancer

    Article • Breast Cancer Research and Treatment, December 2008, Springer Science + Business Media

    Khandan Keyomarsi

  85. A novel MCM-2 fragment with potential biological function in senescence

    Article • Cell Cycle, November 2008, Taylor & Francis

    Khandan Keyomarsi

  86. Biomarkers in Neoadjuvant Trials

    Article • October 2008, Springer Science + Business Media

    Khandan Keyomarsi

  87. Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma Model

    Article • Cancer Research, September 2008, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  88. Synchronization of the cell cycle using Lovastatin

    Article • Cell Cycle, August 2008, Taylor & Francis

    Khandan Keyomarsi

  89. Differential Regulation of Elafin in Normal and Tumor-Derived Mammary Epithelial Cells Is Mediated by CCAAT/Enhancer Binding Protein β

    Article • Cancer Research, December 2007, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  90. The Double-Stranded RNA-Activated Protein Kinase Mediates Radiation Resistance in Mouse Embryo Fibroblasts through Nuclear Factor κB and Akt Activation

    Article • Clinical Cancer Research, October 2007, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  91. Cyclin E–Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy

    Article • Clinical Cancer Research, August 2007, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  92. Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway

    Article • Cancer Research, August 2007, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  93. Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel?

    Article • January 2007, Springer Science + Business Media

    Khandan Keyomarsi

  94. The Differential Staurosporine-Mediated G1 Arrest in Normal versus Tumor Cells Is Dependent on the Retinoblastoma Protein

    Article • Cancer Research, October 2006, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  95. Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome

    Article • Cancer Research, January 2006, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  96. Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer

    Article • Journal of Cellular Physiology, January 2006, Wiley

    Khandan Keyomarsi

  97. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry

    Article • Cancer, October 2005, Wiley

    Khandan Keyomarsi

  98. Author reply

    Article • Cancer, October 2005, Wiley

    Khandan Keyomarsi

  99. Atypical PKCι contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer

    Article • Proceedings of the National Academy of Sciences, August 2005, Proceedings of the National Academy of Sciences

    Khandan Keyomarsi

  100. Cyclin E as a prognostic and predictive marker in breast cancer

    Article • Seminars in Cancer Biology, August 2005, Elsevier

    Khandan Keyomarsi

  101. Targeting the cell cycle for prognosis and therapy of breast cancer

    Article • June 2005, Springer Science + Business Media

    Khandan Keyomarsi

  102. The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27

    Article • Journal of Biological Chemistry, February 2005, American Society for Biochemistry & Molecular Biology (ASBMB)

    Khandan Keyomarsi

  103. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome

    Article • July 2004, Springer Science + Business Media

    Khandan Keyomarsi

  104. Role of cell cycle in mediating sensitivity to radiotherapy

    Article • International Journal of Radiation Oncology*Biology*Physics, July 2004, Elsevier

    Khandan Keyomarsi

  105. Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer

    Article • Cancer Research, May 2004, American Association for Cancer Research (AACR)

    Khandan Keyomarsi

  106. Cyclin E deregulation alters the biologic properties of ovarian cancer cells

    Article • Oncogene, March 2004, Springer Science + Business Media

    Khandan Keyomarsi

  107. Activation of Cyclin-dependent Kinase 2 by Full Length and Low Molecular Weight Forms of Cyclin E in Breast Cancer Cells

    Article • Journal of Biological Chemistry, December 2003, American Society for Biochemistry & Molecular Biology (ASBMB)

    Khandan Keyomarsi

  108. Cyclin E in Breast Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2003, New England Journal of Medicine (NEJM/MMS)

    Khandan Keyomarsi

  109. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation

    Article • Nature Medicine, February 2003, Springer Science + Business Media

    Khandan Keyomarsi

  110. Cyclin E and Survival in Patients with Breast Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2002, New England Journal of Medicine (NEJM/MMS)

    Khandan Keyomarsi

  111. Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms

    Article • Molecular and Cellular Biology, September 2001, ASM Journals

    Khandan Keyomarsi

  112. Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase

    Article • Science, August 2001, American Association for the Advancement of Science

    Khandan Keyomarsi

  113. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53

    Article • Oncogene, January 2001, Springer Science + Business Media

    Khandan Keyomarsi

  114. Erratum to “Expression of an estrogen receptor alpha variant protein in cell lines and tumors”

    Article • Molecular and Cellular Endocrinology, August 2000, Elsevier

    Khandan Keyomarsi

  115. Expression of an estrogen receptor alpha variant protein in cell lines and tumors

    Article • Molecular and Cellular Endocrinology, April 2000, Elsevier

    Khandan Keyomarsi

  116. The Biphasic Induction of p21 and p27 in Breast Cancer Cells by Modulators of cAMP Is Posttranscriptionally Regulated and Independent of the PKA Pathway

    Article • Experimental Cell Research, October 1999, Elsevier

    Khandan Keyomarsi

  117. Lovastatin-mediated G 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

    Article • Proceedings of the National Academy of Sciences, July 1999, Proceedings of the National Academy of Sciences

    Khandan Keyomarsi

  118. Molecular Cloning, Characterization, and Regulation of the Human Mitochondrial Serine Hydroxymethyltransferase Gene

    Article • Journal of Biological Chemistry, January 1997, American Society for Biochemistry & Molecular Biology (ASBMB)

    Khandan Keyomarsi

  119. The role of cyclin E in cell proliferation, development and cancer

    Article • January 1997, Springer Science + Business Media

    Khandan Keyomarsi

  120. Cyclin E, a redundant cyclin in breast cancer

    Article • Proceedings of the National Academy of Sciences, December 1996, Proceedings of the National Academy of Sciences

    Khandan Keyomarsi

  121. Synchronization of mammalian cells by Lovastatin

    Article • Methods in Cell Science, June 1996, Springer Science + Business Media

    Khandan Keyomarsi

  122. Synthesis and Biological Activity of N.omega.-Hemiphthaloyl-.alpha.,.omega.-diaminoalkanoic Acid Analogs of Aminopterin and 3',5-Dichloroaminopterin

    Article • Journal of Medicinal Chemistry, July 1994, American Chemical Society (ACS)

    Khandan Keyomarsi

  123. Molecules of Deregulated Cell Cycle Control in Cancer

    Article • January 1994, Springer Science + Business Media

    Khandan Keyomarsi

  124. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

    Article • Cell, November 1993, Elsevier

    Khandan Keyomarsi

  125. Redundant cyclin overexpression and gene amplification in breast cancer cells.

    Article • Proceedings of the National Academy of Sciences, February 1993, Proceedings of the National Academy of Sciences

    Khandan Keyomarsi

  126. Modification of cell proliferation with inhibitors

    Article • Current Biology, May 1992, Elsevier

    Khandan Keyomarsi

  127. Modification of cell proliferation with inhibitors

    Article • Current Opinion in Cell Biology, April 1992, Elsevier

    Khandan Keyomarsi

  128. Modification of cell proliferation with inhibitors

    Article • Current Biology, April 1992, Elsevier

    Khandan Keyomarsi

  129. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.

    Article • Proceedings of the National Academy of Sciences, November 1990, Proceedings of the National Academy of Sciences

    Khandan Keyomarsi

  130. Drugs in blood donors.

    Article • Clinical Chemistry, January 1987, Oxford University Press (OUP)

    Khandan Keyomarsi

  131. [47] Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with 14C and 3H

    Article • January 1986, Elsevier

    Khandan Keyomarsi

  132. Understanding the Biology of Cancer

    Article • Wiley

    Khandan Keyomarsi

  133. Staurosporine

    Article • Springer Science + Business Media

    Khandan Keyomarsi